Iovance Biotherapeutics to Host First Quarter 2019 Financial Results Conference Call and Webcast on Tuesday, May 7, 2019
May 01 2019 - 7:00AM
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage
biotechnology company developing novel cancer immunotherapies based
on tumor-infiltrating lymphocyte (TIL) technology, today announced
that it will report its first quarter 2019 financial results on
Tuesday, May 7, 2019. Management will host a conference call and
live audio webcast to discuss these results and provide a corporate
update at 4:30 p.m. EDT.
To participate in the conference call, please dial
1-844-646-4465 (domestic) or 1-615-247-0257 (international) and
reference the access code 7393657. A live webcast can be accessed
under “News & Events: Investor Calendar” in the Investors
section of the Company’s website at www.iovance.com or at the
link: https://edge.media-server.com/m6/p/ika42eku. An archived
webcast will be available in the Investors section of
www.iovance.com for thirty days following the call.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize lifileucel, an
autologous cell therapy product using TIL technology that amplifies
the body’s own immune response to eradicate solid tumors or attack
blood cancers. The company is currently conducting the pivotal
study innovaTIL-01 in patients with metastatic melanoma. In
addition, the company’s TIL therapies are being investigated for
the treatment of patients with locally advanced, recurrent or
metastatic cancers including cervical, head and neck, and non-small
cell lung cancer. For more information, please
visit http://www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release are
“forward-looking statements” of Iovance Biotherapeutics, Inc.
(hereinafter referred to as the “Company,” “we,” “us,” or “our”).
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “continue,” “estimates,” “anticipates,” “expects,”
“likely,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. The
forward-looking statements include, but are not limited to, risks
and uncertainties relating to the success, timing, projected
enrollment, manufacturing capabilities, and cost of our ongoing
clinical trials and anticipated clinical trials for our current
product candidates, such as statements regarding the timing of
initiation and completion of these trials; the timing of and our
ability to obtain and maintain U.S. Food and Drug Administration
(“FDA”) or other regulatory authority approval of, or other action
with respect to, our product candidates; the strength of Company’s
product pipeline; the successful implementation of the Company’s
research and development programs and collaborations; the success
of the Company’s manufacturing, license or development agreements;
the time of and our ability to commercialize our product
candidates; the acceptance by the market of the Company’s product
candidates, if approved; and other factors, including general
economic conditions and regulatory developments, not within the
Company’s control. The factors discussed herein could cause actual
results and developments to be materially different from those
expressed in or implied by such statements. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business,
including, without limitation: the FDA may not agree with the
Company’s interpretation of the results of its clinical trials;
later developments with the FDA that may be inconsistent with
already completed FDA meetings; the preliminary clinical results,
including efficacy and safety results, from ongoing Phase 2 studies
may not be reflected in the final analyses of these trials,
including new cohorts within these trials, and may not be
supportive of product approval; the FDA or other regulatory
authorities may potentially delay the timing of their approval of,
or other action with respect to, the Company’s product candidates
(specifically, the Company’s description of FDA interactions are
subject to FDA’s interpretation, as well as FDA’s authority to
request new or additional information); the Company’s ability to
address FDA or other regulatory authority requirements relating to
its clinical programs and registrational plans, such requirements
including, but not limited to, clinical and safety requirements as
well as manufacturing and control requirements; risks related to
the Company’s accelerated FDA review designations, including the
Company’s ability to maintain and benefit from such designations;
and the ability of the Company to manufacture its therapies using
third party manufacturers. A further list and description of
the Company’s risks, uncertainties and other factors can be found
in the Company’s most recent Annual Report on Form 10-K and the
Company's subsequent filings with the Securities and Exchange
Commission. Copies of these filings are available online at
www.sec.gov or www.iovance.com. The forward-looking statements are
made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances.
Investor Relations Contacts: Annie
ChangSolebury Trout646-378-2972achang@troutgroup.com
Chad RubinSolebury Trout646-378-2947crubin@troutgroup.com
Media Relations Contact: Rich AllanSolebury
Trout646-378-2958rallan@troutgroup.com
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024